Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 237.27% | 110.06% | 200.61% | -88.89% | 64.57% |
| Total Depreciation and Amortization | 21.27% | 7.72% | -2.49% | -2.56% | -4.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 159.49% | -13.82% | -44.59% | 123.17% | -74.28% |
| Change in Net Operating Assets | -63.02% | -44.33% | 204.15% | -9,244.44% | 153.03% |
| Cash from Operations | 21.10% | -6.75% | 94.38% | -58.40% | 351.41% |
| Capital Expenditure | -1,425.00% | -131.25% | -14.29% | 80.00% | 76.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 78.53% | 22.74% | 21.79% | 38.93% | -235.32% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -34.16% | -- |
| Cash from Investing | 72.64% | -403.72% | 20.10% | 22.59% | -225.46% |
| Total Debt Issued | -- | -- | -- | -34.53% | -- |
| Total Debt Repaid | 91.47% | -121.09% | -10,078.79% | 89.03% | -74,198.11% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13.61% | -16.02% | -21.50% | 24.93% | -50.86% |
| Cash from Financing | 70.57% | -82.78% | -364.36% | -762.21% | -727.40% |
| Foreign Exchange rate Adjustments | -477.50% | 176.92% | -134.92% | -323.33% | 266.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.00% | -139.82% | 17.91% | -177.92% | -2,918.18% |